9-氯-11beta,17,21-三羟基-16beta-甲基孕甾-1,4-二烯-3,20-二酮17-戊酸酯 | 52619-18-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 9-氯-11beta,17,21-三羟基-16beta-甲基孕甾-1,4-二烯-3,20-二酮17-戊酸酯
• 中文别名: 1H-吲哚-5-羧酸,3-(氨基甲基)-,甲基酯
• 英文名称: Beclomethasone valerate
• 英文别名: [(8S,9R,10S,11S,13S,14S,16S,17R)-9-chloro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] pentanoate
• CAS: 52619-18-8
• 化学式: C₂₇H₃₇ClO₆
• 分子量: 493.0
• InChiKey: CYBACPSHBXABHX-SUYDQAKGSA-N

物化性质

• 熔点：
  195-197°C
• 溶解度：
  二恶烷（轻微）、DMSO（轻微）、甲醇（轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Devices for treating pulmonary vasoconstriction and asthma
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：EP0786264A2

  公开（公告）日：1997-07-30

  A method for treating or preventing bronchoconstriction or reversible pulmonary vasoconstriction in a mammal, which method includes causing the mammal to inhale a therapeutically-effective concentration of gaseous nitric oxide (1,10) or a therapeutically-effective amount of a nitric oxide-releasing compound (106), and an inhaler device (102) containing nitric oxide gas and/or a nitric oxide-releasing compound.

  一种治疗或预防哺乳动物支气管收缩或可逆性肺血管收缩的方法，该方法包括使哺乳动物吸入治疗有效浓度的气态一氧化氮（1,10）或治疗有效量的一氧化氮释放化合物（106），以及含有一氧化氮气体和/或一氧化氮释放化合物的吸入器装置（102）。
• Treatment of pulmonary vasoconstriction and asthma
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：EP1466641A1

  公开（公告）日：2004-10-13

  This invention inter alia relates to a device for the administration of an active agent in a propellant gas into the respiratory system of a patient, said device containing said active agent (106) and a propellant gas in compressed or liquified form, characterised in that said active agent is a phophodiesterase inhibitor.

  本发明尤其涉及一种将活性剂与推进气体一起注入患者呼吸系统的装置，所述装置包含所述活性剂（106）和压缩或液化形式的推进气体，其特征在于所述活性剂是一种噬磷酸二酯酶抑制剂。
• Device in the treatment of pulmonary vasoconstriction and asthma
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：EP1516639A1

  公开（公告）日：2005-03-23

  A method for treating or preventing bronchoconstriction or reversible pulmonary vasoconstriction in a mammal, which method includes causing the mammal to inhale a therapeutically-effective concentration of gaseous nitric oxide (1,10) or a therapeutically-effective amount of a nitric oxide-releasing compound (106), and an inhaler device (102) containing nitric oxide gas and/or a nitric oxide-releasing compound.

  一种治疗或预防哺乳动物支气管收缩或可逆性肺血管收缩的方法，该方法包括使哺乳动物吸入治疗有效浓度的气态一氧化氮（1,10）或治疗有效量的一氧化氮释放化合物（106），以及含有一氧化氮气体和/或一氧化氮释放化合物的吸入器装置（102）。
• Use of NO for the treatment or prevention of reversible pulmonary vasoconstriction
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：EP1875917A2

  公开（公告）日：2008-01-09

  A method for treating or preventing bronchoconstriction or reversible pulmonary vasoconstriction in a mammal, which method includes causing the mammal to inhale a therapeutically-effective concentration of gaseous nitric oxide (1,10) or a therapeutically-effective amount of a nitric oxide-releasing compound (106), and an inhaler device (102) containing nitric oxide gas and/or a nitric oxide-releasing compound.

  一种治疗或预防哺乳动物支气管收缩或可逆性肺血管收缩的方法，该方法包括使哺乳动物吸入治疗有效浓度的气态一氧化氮（1,10）或治疗有效量的一氧化氮释放化合物（106），以及含有一氧化氮气体和/或一氧化氮释放化合物的吸入器装置（102）。
• Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
  申请人：Amgen, Inc.

  公开号：US20020010318A1

  公开（公告）日：2002-01-24

  The present invention relates to the pulmonary administration of a therapeutic protein by means of powdered pharmaceutical compositions suitable for inhalation therapy. In particular the invention relates to dry powder formulations of secretory leukocyte protease inhibitor (SLPI) for pulmonary delivery. Exemplary pharmaceutical compositions contain SLPI and a pharmaceutically acceptable carrier in the form of a dry powder which is typically less than about 10% by weight water. About 50% to 95% by mass of the powder comprises particles or agglomerates of particles having a diameter within the range of from about 1.0 microns to about 8 microns, with a mass median diameter ranging from about 3.0 microns to about 6 microns.

  本发明涉及通过适用于吸入疗法的粉末状药物组合物对治疗性蛋白质进行肺部给药。本发明尤其涉及用于肺部给药的分泌性白细胞蛋白酶抑制剂（SLPI）的干粉制剂。示例性药物组合物含有SLPI和药学上可接受的载体，其形式为干粉，按重量计水分通常小于约10%。粉末中约 50%至 95%（按重量计）的颗粒或颗粒团聚体的直径在约 1.0 微米至约 8 微米的范围内，质量中值直径在约 3.0 微米至约 6 微米的范围内。